Trans-Tasman drug developer Aft Pharmaceuticals is targeting lucrative niche diseases its Big Pharma rivals have ignored ...

Newly recognized issues, including extreme fatigue with excessive weight reduction, bone loss, and abdominal pain, point to ...

Biotechs have faced several challenging years with slumping valuations and a competitive funding environment. However, the latest slew of ...

Roche, along with Bristol Myers Squibb, Novo Nordisk, AbbVie, Eli Lilly and others, is making inroads into molecular glues to ...

Zealand Pharma A/S, a biotechnology company, has appointed Steven Johnson as Chief Development Officer.

Novo Nordisk CEO's ouster signals stiff competition in the obesity market, getting dominated by Eli Lilly, with Roche, ...

Precision Oncology market is set for strong growth through 2035, fueled by genomic advances, rising cancer cases, and increased use of targeted therapies.

“We are incredibly excited to launch this partnership, which represents a step change to realize Zealand Pharma's vision of becoming a key player in the future management of obesity. Roche ...

“We are incredibly excited to launch this partnership, which represents a step change to realize Zealand Pharma’s vision of becoming a key player in the future management of obesity. Roche ticked all ...

Zealand Pharma announces closing of collaboration and license agreement with Roche Copenhagen, Denmark, May 9, 2025 - Zealand Pharma A/S ("the Company" or "Zealand Pharma") (Nasdaq: ZEAL ...

Copenhagen, Denmark, May 9, 2025 – Zealand Pharma A/S ("the Company" or “Zealand Pharma”) (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development ...